Q-omics provides the consensus-scored LGALS13 profile across patient tissues and cancer cell-line models. LGALS13 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LGALS13 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, LGALS13 RNA expression shows 6,306 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, THCA, and STAD as cancer lineages where LGALS13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LGALS13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LGALS13 survival associations across molecular data types. LGALS13 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LGALS13 RNA expression–survival associations across cancer types. High LGALS13 expression shows unfavorable associations in BLCA, MESO, READ, THYM, UCS and UVM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LGALS13 RNA expression.
This table summarizes LGALS13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LGALS13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LGALS13 shows higher tumor expression in THCA. The THCA box plot shows higher LGALS13 RNA expression in tumor versus normal tissue (log2 FC = +0.205, t-test p = .019).
This table shows molecular features associated with LGALS13 in patient tissues and cancer cell lines. In patient samples, LGALS13 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LGALS13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and OVARY.
